CLCarlos Lumbreras

Carlos Lumbreras

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Carlos Lumbreras has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Understanding Post-COVID Dyspnea: Clinical and Functional Insights from Long COVID Patients

    by Jesus Alonso-Carrillo, Cristina de la Calle, Pilar Parra, Maria Ruiz Rodriguez, Estibaliz Arrieta Ortubay, Ana Roca, Mario Diaz Santiañez, Antonio Lalueza, Rocio Garcia-Garcia, Carlos Lumbreras Bermejo, et al.

    Objective: Long COVID (LC) has been defined as a chronic condition that occurs after SARS-CoV-2 infection and persists for more than 3 months. Dyspnea is the most common and disabling symptom with several mechanisms identified. The pathophysiology of post-COVID dyspnea is unknown. The aim of this study is to analyze the clinical profile of patients presenting with dyspnea in the context of LC and to assess its possible relation with complementary diagnostic tests. Material and Methods: This is a retrospective cohort study including adult patients diagnosed with LC attending a post-COVID outpatient clinic. Dyspnea was assessed using mMRC and Borg scales. Complementary tests included chest imaging, pulmonary function tests (PFTs) and a six-minute walk test (6MWT). These assessments were performed at several time points throughout follow-up (3, 6, and 12 months). Results: Eighty patients diagnosed with LC were included, the mean age was 60.0 ± 14.4 and 43 (54.8%) were female. Most patients were hospitalized during acute infection (97.5%) and 25 patients experienced respiratory failure. During the follow-up, chest X-rays showed persistent abnormalities in 67.5% of patients, and 6MWT was pathological in 61.3% at 277 days (IQR 176–326) after acute infection. No significant differences were observed in the prevalence of ventilatory failure across dyspnea severity categories. Reduced DLCO was observed in 20% of patients, while obstructive or restrictive patterns were infrequent. Through three follow-up visits, pulmonary function and exercise capacity remained stable, with modest improvements in DLCO and exercise-induced desaturation (p = 0.005). In multivariable analysis, obesity (adjusted OR 7.88; p = 0.023) and lower DLCO (p = 0.049) were independent predictors of more severe dyspnea, highlighting the role of non-pulmonary factors in Long COVID. Conclusions: This study describes the clinical and functional profile of a cohort of patients with LC. Although abnormal findings were frequent, only impaired DLCO and obesity were independently associated with dyspnea severity, while imaging and six-minute walk test abnormalities showed no consistent association with symptom intensity, supporting a multifactorial origin of post-COVID dyspnea.

  • Open Access

    Intravenous Administration of Remdesivir at the Acute Phase of SARS-CoV-2 Infection Is Associated with a Lower Prevalence of Post-COVID-19 Pain

    by César Fernández-De-Las-Peñas, Anabel Franco-Moreno, María Ruiz-Ruigómez, Estibaliz Arrieta-Ortubay, Pablo Ryan-Murua, Carlos Lumbreras-Bermejo, Pablo Del-Valle-Loarte, Oscar J. Pellicer-Valero, Juan Torres-Macho, Rocco Giordano, et al.

    Background/Objective: Evidence suggests that the administration of antivirals at the acute phase of SARS-CoV-2 infection is associated with lower COVID-19 severity, accordingly, the administration of antivirals at the acute phase of the infection could prevent post-COVID-19 symptoms. The current study investigated the effects of the intravenous administration of Remdesivir at hospitalization (acute phase of SARS-CoV-2 infection) in COVID-19 survivors on the development of post-COVID-19 pain symptoms. Methods: A cohort of previously hospitalized COVID-19 survivors who received intravenous administration of Remdesivir at the acute COVID-19 phase (n = 216) were matched with a cohort of previously hospitalized COVID-19 survivors who did not receive any antiviral treatment at the acute phase of the infection (n = 216). In a face-to-face interview, they were asked for the development of pain symptoms attributed to SARS-CoV-2 infection and whether the symptom persisted at the time of the study (mean follow-up: 18.4, SD: 0.8 months). Clinical/hospitalization data were collected from medical records. Anxiety/depressive symptoms and sleep quality were also assessed with validated self-reported questionnaires. Results: No differences in hospitalization data and the presence of previous chronic conditions were seen between patients receiving or not receiving intravenous administration of Remdesivir during hospitalization. The multivariate analysis revealed that the intravenous administration of Remdesivir at the acute COVID-19 phase was a protective factor for the development of overall post-COVID-19 pain (OR 0.444, 95% CI 0.292–0.674, p < 0.001). A protective effect of administrating intravenous Remdesivir was specifically seen for thorax/chest (OR 0.277, 95% CI 0.100–0.766, p = 0.01) and lumbar spine (OR 0.347, 95% CI 0.143–0.844, p = 0.02) pain. Conclusions: Current results support a potential protective role of the intravenous administration of Remdesivir at the acute phase of SARS-CoV-2 infection for developing long-term post-COVID-19 pain in previously hospitalized COVID-19 survivors. Studies investigating the effects of the oral administration of antivirals in non-hospitalized populations are needed to generalize these findings.

  • Open Access

    Efficacy of Ceftobiprole and Daptomycin at Bone Concentrations Against Methicillin-Resistant Staphylococcus aureus Biofilm: Results of a Dynamic In Vitro PK/PD Model

    by Mikel Mancheño-Losa, María Ángeles Meléndez-Carmona, Carlos Lumbreras, Jaime Lora-Tamayo

    Background: The presence of biofilms and low antimicrobial concentrations in bone tissue make prosthetic joint infections (PJI) difficult to treat. Ceftobiprole (CTO) has a potential role in MRSA PJI. This study evaluated the efficacy of ceftobiprole and daptomycin (DAP) alone and in combination against MRSA biofilms at expected bone tissue concentrations. We assessed whether CTO-DAP outperformed DAP combined with a non-anti-MRSA beta-lactam (cefazolin [CZO]). Methods: A dynamic in vitro PK/PD biofilm model (CDC biofilm reactor) was used to simulate concentrations expected in cortical bone at a standard dosing of DAP (10 mg/kg/24 h), CTO (500 mg/8 h), and CZO (2 g/8 h), and assess performance against a 48-h MRSA biofilm from two clinical isolates that cause PJI (MRSA-1811 and MRSA-1733). Time–kill curves using the log change method (Δlog10 CFU/cm2) assessed antimicrobial efficacy over 56 h. Resistance emergence was monitored. Results: Although both monotherapies were active, neither reached bactericidal levels nor was one superior to the other (Δlog10 CFU/cm2 CTO vs. DAP: −1.44 ± 0.25 vs. −1.50 ± 0.01 [p = 0.686] and −1.55 ± 0.74 vs. −0.56 ± 0.36 [p = 0.108] for MRSA-1811 and MRSA-1733, respectively). Only in the MRSA-1811 isolate did the CTO-DAP combination improve the activity of each monotherapy, without achieving a synergistic effect (Δlog10 CFU/cm2: CTO-DAP −2.087 ± 0.048 vs. CTO −1.436 ± 0.249 [p = 0.013] and vs. DAP −1.503 ± 0.011 [p = 0.006]). No combination therapy (CTO-DAP vs. DAP-CZO) outperformed the other in either strain. No resistant bacterial subpopulations appeared with any antibiotic regimen. Conclusions: At clinically relevant concentrations, ceftobiprole and daptomycin showed similar activity against MRSA biofilms. The CTO-DAP combination showed comparable efficacy to DAP-CZO.


  • Open Access

    Periprosthetic Infection of Transfibular Ankle Arthroplasties Managed with Implant Retention: Anatomical Limitations of Surgical Debridement

    by Pilar Hernández-Jiménez, Mikel Mancheño-Losa, María Ángeles Meléndez-Carmona, M Ángela Mellado-Romero, Patricia Brañas, Carlos Lumbreras-Bermejo, Jesús Enrique Vilá Y Rico, Jaime Lora-Tamayo

    Background: Prosthetic ankle infection is an infrequent and rarely explored prosthetic joint infection (PJI). In early infection, the debridement of implants inserted using the transfibular approach has certain peculiarities that pose a diagnostic and therapeutic challenge, the impact of which on infection prognosis is still unknown. Methods: This study prospectively collected all cases of transfibular prosthetic ankle infection at a tertiary hospital between 2014 and 2022, describing their demographic, clinical, microbiological, and management characteristics, along with the outcome over a long follow-up. This cohort was compared with a cohort of infected fibular plates without prostheses implanted in the same period of time. Results: Seven cases of ankle PJI were analysed, all of them implanted using a transfibular approach. They were all early prosthetic infections. The median age was 63 years (range 54–74) with a predominance of women (71.4%), three patients with diabetes (42.9%), and one patient with rheumatoid arthritis (14.3%). The aetiology was predominantly staphylococcal (4 [57.1%] methicillin-susceptible S. aureus and 1 [14.3%] S. epidermidis). All cases were managed with irrigation and debridement limited to the fibular plate, four of which failed (57%). By comparison, eleven cases of infected fibular plates without prostheses implanted were analysed. There were no differences in clinical, microbiological, or therapeutic management characteristics between the groups. Failure among infected fibular plates occurred in only two cases (18%). Conclusions: Debridement of infected transfibular ankle prostheses suggests a worse evolution than would be expected for other joint infections. This could be explained by the nature of the debridement, limited to the fibular component. Further detailed studies of the surgical possibilities in prosthetic ankle infections are necessary to improve the prognosis of these infections, given their impact on joint function.


  • Open Access

    Is Antiviral Treatment with Remdesivir at the Acute Phase of SARS-CoV-2 Infection Effective for Decreasing the Risk of Long-Lasting Post-COVID Symptoms?

    by César Fernández-De-Las-Peñas, Anabel Franco-Moreno, María Ruiz-Ruigómez, Estibaliz Arrieta-Ortubay, Pablo Ryan-Murua, Carlos Lumbreras-Bermejo, Pablo Del-Valle-Loarte, Oscar J. Pellicer-Valero, Rocco Giordano, Lars Arendt-Nielsen, et al.

    The aim of this study was to investigate the effects of administrating Remdesivir at the acute COVID-19 phase on developing post-COVID symptoms in previously hospitalized COVID-19 survivors by controlling factors such as age, sex, body mass index, and vaccination status. A case-control study was performed. Hospitalized COVID-19 survivors who had received intravenous Remdesivir during the acute phase (n = 216) were matched by age, sex, body mass index, and vaccination status with survivors who did not receive antiviral treatment (n = 216). Participants were asked to self-report the presence of any post-COVID symptom (defined as a symptom that started no later than three months after infection) and whether the symptom persisted at the time of study (mean: 18.4, SD: 0.8 months). Anxiety levels (HADS-A), depressive symptoms (HADS-D), sleep quality (PSQI), and severity/disability (FIC) were also compared. The multivariate analysis revealed that administration of Remdesivir at the acute COVID-19 phase was a protective factor for long-term COVID development (OR0.401, 95%CI 0.256–0.628) and specifically for the following post-COVID symptoms: fatigue (OR0.399, 95%CI 0.270–0.590), pain (OR0.368, 95% CI 0.248–0.548), dyspnea at rest (OR0.580, 95%CI 0.361–0.933), concentration loss (OR0.368, 95%CI 0.151–0.901), memory loss (OR0.399, 95%CI 0.270–0.590), hair loss (OR0.103, 95%CI 0.052–0.207), and skin rashes (OR0.037, 95%CI 0.005–0.278). This study supports the potential protective role of intravenous administration of Remdesivir during the COVID-19 acute phase for long-lasting post-COVID symptoms in previously hospitalized COVID-19 survivors.


  • Open Access

    Bacteremia in Patients with Solid Organ Cancer: Insights into Epidemiology and Antibiotic Consumption

    by Begoña de Dios-García, Guillermo Maestro, Carmen Díaz-Pedroche, Wagner Parra, Óscar Campos, María Ángeles Orellana, José Manuel Caro, Carlos Lumbreras, Manuel Lizasoain

    Epidemiology and risk factors associated to bacterial resistance in solid organ cancer (SOC) patients has been barely described. This retrospective monocentric study analyzed clinical variables in SOC patients who developed bacteremia between 1 January 2019 and 31 December 2022. We described rates of bacterial resistance in Gram negative bacteria (80.6%): E. coli-ESBL, K. pneumoniae-ESBL, Carbapenem-Resistant K. pneumoniae and Meropenem-Resistant P. aeruginosa, as well as antibiotic consumption, and compared these rates between the medical and oncology wards. In total, we included 314 bacteremias from 253 patients. SOC patients are frequently prescribed antibiotics (40.8%), mainly fluoroquinolones. Nosocomial bacteremia accounted for 18.2% of the cases and only 14.3% of patients were neutropenic. Hepatobiliary tract was the most frequent tumor (31.5%) and source of bacteremia (38.5%). Resistant bacteria showed a decreased rate of resistance during the years studied in the oncology ward. Both K-ESBL and K-CBP resistance rates decreased (from 45.8% to 20.0%, and from 29.2% to 20.0%, respectively), as well as MRPA, which varied from a resistance rate of 28% to 16.7%. The presence of a urinary catheter (p < 0.001) and previous antibiotic prescription (p = 0.002) were risk factors for bacterial resistance. Identifying either of these risk factors could help in guiding antibiotic prescription for SOC patients.


  • Open Access

    An Early Th1 Response Is a Key Factor for a Favorable COVID-19 Evolution

    by Francisco Javier Gil-Etayo, Sara Garcinuño, Alberto Utrero-Rico, Oscar Cabrera-Marante, Daniel Arroyo-Sanchez, Esther Mancebo, Daniel Enrique Pleguezuelo, Edgard Rodríguez-Frías, Luis M. Allende, Pablo Morales-Pérez, et al.

    The Th1/Th2 balance plays a crucial role in the progression of different pathologies and is a determining factor in the evolution of infectious diseases. This work has aimed to evaluate the early, or on diagnosis, T-cell compartment response, T-helper subsets and anti-SARS-CoV-2 antibody specificity in COVID-19 patients and to classify them according to evolution based on infection severity. A unicenter, randomized group of 146 COVID-19 patients was divided into four groups in accordance with the most critical events during the course of disease. The immunophenotype and T-helper subsets were analyzed by flow cytometry. Asymptomatic SARS-CoV-2 infected individuals showed a potent and robust Th1 immunity, with a lower Th17 and less activated T-cells at the time of sample acquisition compared not only with symptomatic patients, but also with healthy controls. Conversely, severe COVID-19 patients presented with Th17-skewed immunity, fewer Th1 responses and more activated T-cells. The multivariate analysis of the immunological and inflammatory parameters, together with the comorbidities, showed that the Th1 response was an independent protective factor for the prevention of hospitalization (OR 0.17, 95% CI 0.03–0.81), with an AUC of 0.844. Likewise, the Th1 response was found to be an independent protective factor for severe forms of the disease (OR 0.09, 95% CI: 0.01–0.63, p = 0.015, AUC: 0.873). In conclusion, a predominant Th1 immune response in the acute phase of the SARS-CoV-2 infection could be used as a tool to identify patients who might have a good disease evolution.


  • Open Access

    A Short Corticosteroid Course Reduces Symptoms and Immunological Alterations Underlying Long-COVID

    by Alberto Utrero-Rico, María Ruiz-Ruigómez, Rocío Laguna-Goya, Estíbaliz Arrieta-Ortubay, Marta Chivite-Lacaba, Cecilia González-Cuadrado, Antonio Lalueza, Patricia Almendro-Vazquez, Antonio Serrano, José María Aguado, et al.

    Despite the growing number of patients with persistent symptoms after acute SARS-CoV-2 infection, the pathophysiology underlying long-COVID is not yet well characterized, and there is no established therapy. We performed a deep immune profiling in nine patients with persistent symptoms (PSP), before and after a 4-day prednisone course, and five post-COVID-19 patients without persistent symptoms (NSP). PSP showed a perturbed distribution of circulating mononuclear cell populations. Symptoms in PSP were accompanied by a pro-inflammatory phenotype characterized by increased conventional dendritic cells and augmented expression of antigen presentation, co-stimulation, migration, and activation markers in monocytes. The adaptive immunity compartment in PSP showed a Th1-predominance, decreased naïve and regulatory T cells, and augmentation of the PD-1 exhaustion marker. These immune alterations reverted after the corticosteroid treatment and were maintained during the 4-month follow-up, and their normalization correlated with clinical amelioration. The current work highlights an immunopathogenic basis together with a possible role for steroids in the treatment for long-COVID.